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Is it Form or Function?
The “COURAGE” to Ask*
Spencer B. King, III, MD
Atlanta, Georgia
Treatment selection for stable ischemic heart disease pa-
tients remains a work in progress. The stable ischemic heart
disease guidelines published in 2012 (1) address 2 pathways
to progress from medical therapy only toward revasculari-
zation: unsatisfactorily controlled symptoms or high-risk
features on the basis of noninvasive testing. For patients
without compelling symptoms, the risk stratiﬁcation by
noninvasive ischemia testing provides the gateway to move
beyond medical therapy only. The ongoing ISCHEMIA
(International Study of Comparative Health Effectiveness
With Medical and Invasive Approaches) trial (2) is using
this measure in an attempt to identify a relatively high-riskSee page 195group in whom revascularization may be beneﬁcial. Much
of the rationale for the trial springs from the failure of the
COURAGE (Clinical Outcomes Utilizing Revasculariza-
tion and Aggressive Drug Evaluation) trial (3) or the BARI
2D (Bypass Angioplasty Revascularization Investigation
2 Diabetes) trial (4) to show a survival beneﬁt for revascu-
larization, and therefore a group with increased cardiovas-
cular risk using improved revascularization technology will
be tested in the ISCHEMIA trial.
A most interesting substudy of the COURAGE trial by
Mancini et al. (5), which set out to explore the impact of the
anatomic and ischemic burden of disease as well as any
synergistic effect on clinical outcomes, is reported in this
issue of JACC: Cardiovascular Interventions. The in-
vestigators studied 621 patients who had both baseline
angiograms and single-photon emission computed tomo-
graphy imaging studies. An anatomic burden score was
created to reﬂect the degree of myocardial jeopardy pro-
duced by stenotic lesions. To determine independent pre-
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ysis was used. The overall outcomes of the COURAGE
trial are well known, so it was no surprise that the 313 pa-
tients with optimal medical therapy plus percutaneous cor-
onary intervention did not differ from the 308 patients
assigned to optimal medical therapy alone. Although the
number of patients in this substudy is modest, the baseline
characteristics were quite similar to the overall COURAGE
trial. Whereas the treatment assignment did not predict
outcomes, the impact of the quantitative anatomic burden
“form” and the ischemic burden “function” were quite
interesting. The degree of ischemia did not predict the
clinical outcome, whereas the extent of anatomic obstruction
of the coronary arteries did. Left ventricular dysfunction was,
as expected, also a predictor of adverse events. So, 2 points
were established. First, neither the coronary anatomy nor
myocardial ischemia nor the combination of the 2 interacted
with the therapeutic assignment to predict outcome. Second,
which is perhaps more interesting, was that left ventricular
ejection fraction and the anatomic burden of disease at
baseline were predictors of the combined endpoints of death,
myocardial infarction, or non–ST-segment elevation acute
coronary syndromes, but the ischemic burden was not.
These ﬁndings may have implications for the ongoing
ISCHEMIA trial and for the selection of revascularization
for patients outside that trial. Clearly, this trial is limited by
the fact that it is a post hoc substudy with a modest sample
size, but the hypothesis that it generates should not be
discounted. To become eligible for the ISCHEMIA trial,
patients must have perfusion imaging that indicates >10%
stress-induced ischemia. Randomization occurs prior to any
angiographic assessment of the anatomic burden of disease.
Patients assigned to medical therapy proceed without an-
giograms, and patients assigned to invasive measures un-
dergo coronary angiography. One might ask, on the basis of
this COURAGE substudy, why the anatomic burden of
disease is a more potent predictor of outcome than the de-
gree of ischemia. The investigators touch on this point, but
perhaps some additional speculation is in order. For patients
with stable ischemic heart disease, ischemia reﬂects the de-
gree of obstruction to blood ﬂow that is hemodynamically
determined. This may result from high-grade stenoses or
total occlusions. One can imagine that a patient with a total
occlusion of an anterior descending coronary artery and
collateral supply from other vessels would have a large
ischemic burden, but if there is not extensive atherosclerosis
in the other vessels, the potential for an acute coronary event
may be limited. Conversely, a patient with an extensive
anatomic burden of disease may have many plaques that are
potentially vulnerable to producing an acute event. In other
words, the presence of ischemia is not what produces most
clinical events but rather the vulnerable plaque that leads to a
sudden occlusion or embolization of a previously functioning
conduit. One might ask in retort why ischemia has always
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203been viewed as a risk factor for clinical events. Patients
with increasing degrees of ischemia are likely to also have
increasing burden of anatomic disease, but in this current
observation on patients having both parameters measured,
the anatomic disease trumps the measure of chronic
ischemia.
What are the implications of this observation for the
ISCHEMIA trial and for selection of therapy outside that
trial? If the anatomic burden of disease is a potent predictor
of outcomes, should the use of angiography in chronic stable
ischemic disease patients be liberalized? That is not an
option in the ISCHEMIA trial where the decision has been
made to use ischemia as the gatekeeper for entry into the
trial. I believe the ﬁndings here provide good news and
bad news for the ISCHEMIA trial. First, the good news.
Because the COURAGE trial consisted mostly of patients
with <10% ischemia, the ISCHEMIA trial will undoubt-
edly include patients with a greater anatomic burden of
disease and who will therefore more likely beneﬁt from
revascularization. On the other hand, the bad news. Because
there is no anatomic burden of disease used in the eligibility
for the trial, some patients with the greatest predictive risk
of events may be excluded. Others with extensive ischemia
but less compelling anatomic burden may be included.
There remains, however, an opportunity to evaluate “form”
versus “function” in this trial. The ISCHEMIA trial has
built into its protocol a baseline computed tomographic
angiogram, the results of which are blinded to the inves-
tigators. The purpose of this study is to eliminate patients
with left main disease who would have not been suitable for
medical therapy alone and to eliminate patients without
signiﬁcant stenoses. Although this computed tomographic
angiogram does not play a role in the selection of patients
for the trial, it will provide a post hoc opportunity to eval-
uate the prognostic importance of the anatomic burden of
disease, and we may learn whether anatomy, once again,
trumps ischemia in this higher-risk study group. For pa-
tients outside the ISCHEMIA trial, the value of the
anatomic burden of disease raises important questionsconcerning algorithms for investigation of patients with
stable ischemic heart disease. Should angiograms be
restricted to patients with higher risk scores from nonin-
vasive evaluations of ischemia, or should some be considered
for angiography? What will be the future role of computed
tomographic angiography be in these patients? Although
this substudy of the COURAGE trial does not answer all of
these questions, it certainly raises the possibility that form
may sometimes trump function in predicting cardiovascular
events.
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